NCT00443573View on ClinicalTrials.gov

Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer

PHASE1/PHASE2SuspendedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

August 31, 2007

Conditions
Colon Cancer
Interventions
DRUG

recombinant nematode anticoagulant protein c2 (rNAPc2)

escalating dose administered 2x/week sq.

Trial Locations (1)

90033

LAC/USC Medical Center, Los Angeles

Sponsors
All Listed Sponsors
lead

ARCA Biopharma, Inc.

INDUSTRY